INJECTION SITE FIBROSIS

This adverse event was reported 117 times

These drugs are most commonly taken by patients reporting INJECTION SITE FIBROSIS:

# Drug Count
0 INTERFERON BETA-1A 17
1 GLATIRAMER ACETATE 10
2 FULVESTRANT 5
3 INSULIN GLARGINE 5
4 INSULIN LISPRO 5
5 OCTREOTIDE ACETATE 5
6 INSULIN DEGLUDEC 4
7 INSULIN HUMAN 4
8 NALTREXONE 4
9 ENALAPRIL 3
See all common drugs associated with INJECTION SITE FIBROSIS

INJECTION SITE FIBROSIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DIFLUNISAL 2 0.0025
1 GLUTATHIONE 2 0.0012
2 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE 1 0.0011
3 SAW PALMETTO 1 0.0005
4 CABOTEGRAVIR AND RILPIVIRINE 2 0.0003
5 DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE 1 0.0003
6 RILPIVIRINE 2 0.0003
7 CABOTEGRAVIR 2 0.0002
8 PEGVALIASE-PQPZ 2 0.0002
9 AMANTADINE HYDROCHLORIDE 1 0.0002
See all drugs enriched for association with INJECTION SITE FIBROSIS

INJECTION SITE FIBROSIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Cytolytic Agent [EPC] 1 0.0004
1 Phenylalanine Metabolizing Enzyme [EPC] 2 0.0002
2 Provitamin D2 Compound [EPC] 4 0.0001
3 Estrogen Receptor Antagonist [EPC] 5 0.0001
4 Interleukin-1 Receptor Antagonist [EPC] 2 0.0001
5 Insulin [EPC] 5 0.0001
6 Interferon beta [EPC] 17 0.0001
7 Vitamin D3 Analog [EPC] 1 0.0000
8 Human Immunoglobulin G [EPC] 1 0.0000
9 Insulin Analog [EPC] 12 0.0000
See all drug classes enriched for association with INJECTION SITE FIBROSIS